SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 3, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced topline results from the phase 2/3 DISTINCT clinical ...
(RTTNews) - United Therapeutics Corp. (UTHR) announced Monday topline results from the phase 2/3 DISTINCT clinical study evaluating Unituxin (dinutuximab) Injection added to irinotecan compared to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results